Haziza, C.; Martin Leroy, C.; Stueber, M.; Lindner, D.; Forte, N.; Magnette, J.
Objective: In clinical studies to assess alternative tobacco products that heat rather than burn tobacco, a compliance biomarker is needed to detect the additional use of conventional cigarettes. Standard biomarkers of exposure to cigarette smoke constituents seem to be not sensitive enough for this purpose. The aim of this research was to identify and characterize a biomarker specific for combusted tobacco. Methods: 2-cyanoethyl mercapturic acid (CEMA), a metabolite of acrylonitrile, was identified as a candidate compliance biomarker. CEMA was analyzed in 24-hour urine samples retained from a clinical study (#NCT00812279) that assessed a test product that heats rather than burns tobacco. The diagnostic accuracy of three different CEMA analysis variables (concentration [CEMAc], amount excreted in 24 hours [CEMAAe24h], CEMA concentration normalized by urinary creatinine [CEMAcreat]) was evaluated by analyzing the receiver operating characteristics (ROC) curves. The diagnostic accuracy of CEMA variables and standard biomarkers of exposure was compared based on the area under the ROC curves. Results: CEMAcreat and CEMAc were able to differentiate between current smokers of conventional cigarettes and both non-smokers and smokers of the test product with high diagnostic accuracy. The performance of CEMAcreat was slightly better than that of CEMAc. Both CEMA variables performed better than standard biomarkers of exposure. Conclusion: The results suggest that CEMAcreat is a suitable biomarker for assessing product compliance in clinical studies assessing alternative tobacco products and allow recommendation of preliminary thresholds to detect recent use of conventional cigarettes based on CEMAcreat levels. This will be verified in future clinical studies.
PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization.
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.